X0203 3/A 2009-02-23 2009-03-05 0 0001013238 ARADIGM CORP ARDM 0001457518 First Eagle Value in Biotechnology Master Fund, Ltd. C/O FIRST EAGLE INV. MGMT, GEN. COUNSEL 1345 AVENUE OF THE AMERICAS NEW YORK NY 10105 0 0 1 1 See remarks. 0001459708 21 APRIL FUND LTD CITCO FUND SERVICES (CAYMAN ISLANDS) LTD REGATTA OFFICE PARK WEST BAY ROAD GRAND CAYMAN E9 KY1-1205 CAYMAN ISLANDS 0 0 1 1 See remarks. 0001459688 21 APRIL FUND LP C/O FIRST EAGLE INV. MGMT., GEN. COUNSEL 1345 AVENUE OF THE AMERICAS, 44TH FLOOR NEW YORK NY 10105 0 0 1 1 See remarks. 0001459975 DEF Associates N.V. C/O CITCO FUND SERVICES (CURACAO) N.V. KAYA FLAMBOYAN 9, P.O. BOX 812 CURACAO P8 00000 NETHERLANDS ANTILLES 0 0 1 1 See remarks. Common Stock 37084262 I See remarks. See remarks. This amended Form 3 is filed to correct the information filed in the original Form 3 filed on March 5, 2009 (the "Original Form 3"). Except for the updating amendment in this amended Form 3, the Original Form 3 remains in effect. The shares reported on this amended Form 3 consist of 19,452,141 shares held by First Eagle Value in Biotechnology Master Fund, Ltd. ("FEVIBMF"), 2,761,679 shares held by 21 April Fund, L.P. ("21 April LP"), 9,870,442 shares held by 21 April Fund, Ltd. ("21 April Ltd.") and 5,000,000 shares held by DEF Associates N.V. (together with FEVIBMF, 21 April LP and 21 April Ltd., the "Funds"). The Funds may be deemed to be members of a Section 13(d) group owning more than 10% of the issuer's outstanding common stock. Each of the Funds disclaims Section 16 beneficial ownership of the reported securities and this report shall not be deemed an admission that any such Fund is the beneficial owner of such securities, except to the extent of its pecuniary interet therein. Dan DeClue 2010-06-22 Dan DeClue 2010-06-22 Dan DeClue 2010-06-22 Dan DeClue 2010-06-22